MYM Nutraceuticals is focused on constructing high quality cannabis growing facilities while building, acquiring, and growing businesses to become a world-class cannabis brand.
MYM through its various joint ventures is currently building three large-scale production facilities in both Canada and Australia. Upon completion of these three projects, the total amount of greenhouse growing space is expected to exceed 2.7 million square feet.
The Weedon Project
The Weedon Project – The 1.5 million sf greenhouse project has been approved by the City of Weedon. A license application has been submitted to Health Canada. MYM has purchased through its partially owned subsidiaries 329 acres of land to build on. This project will include a cannabis museum and a cannabis university for industry training.
The Laval Project
The Laval Project – The facility has been completed and is awaiting licensing from Health Canada. The facility is currently 10,000 sf and will be expanded to 37,000 sf. Once the appropriate licenses are received from Health Canada, it will enable MYM to produce and market its branded THC and CBD medical products across Canada.
The Northern Rivers Project
Casino, New South Wales, Australia
The Northern Rivers Project owned by Solaris Nutraceuticals – a 1.2 million sf greenhouse project which, upon completion, is expected to be the largest cannabis greenhouse in Australia. Subject to receiving the appropriate licenses, the first crop is expected to be planted in the second quarter of 2019. Solaris Nutraceuticals received a AUD $2,500,000 grant from Federal Department of Innovation, Industry & Science for this project. MYM owns 35% of Solaris Nutraceuticals – www.solarisnutraceuticals.com
MYM has purchased a 49% stake in Colombia ORGANICA, a Colombia based company with expertise in the manufacturing of pharmaceutical products, medicinal chemical substances and botanical products. Colombia ORGANICA holds a seed to sale license for low THC cannabis and is in the application process for both high THC cannabis cultivation and extraction. Colombia ORGANICA has existing licensing permits to grow, produce and create cannabis derivatives to be commercialized and/or exported. The company will continue to focus on production of high quality plants that are suited to the unique high altitude, equatorial regions of Antioquia, Colombia. Colombia ORGANICA is in the process of developing and registering seed strains with the Colombia Agriculture Institute.
MJT Manufacturing Project – the 5,000 SF production facility located in Toronto, Ontario is a GMP certified, state of the art extraction lab and production facility dedicated to industrial hemp processing (CBD). This high capacity production space is able to produce large volumes with a high level of consistency. The facility is capable of producing a full range of CBD extracts and isolates. The MJT production facility is focussed on product development for MYM owned brand.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated seventy five hundred dollars for MYM Nutraceuticals Inc. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF MYM Nutraceuticals Inc.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.